Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
66 hedge funds and large institutions have $110M invested in Novelion Therapeutics Inc. Common Shares in 2016 Q4 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
368% more call options, than puts
Call options by funds: $2.85M | Put options by funds: $610K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$17.3M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$13.5M |
| 3 |
AC
Armistice Capital
New York
|
+$12.6M |
| 4 |
SCM
Scopia Capital Management
New York
|
+$10.4M |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$9.08M |
Top Sellers
NVLN Hedge Fund Activity: Q4 2016 in Review
66 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q4 2016, worth a combined $110M.
Buyers outnumbered sellers: 66 funds opened new NVLN positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $17.3M.
- 66 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $110M of Novelion Therapeutics Inc. Common Shares stock for Q4 2016.
- 66 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q4 2016 and 0 closed out, a net change of +66 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q4 2016 was Broadfin Capital, an estimated $17.3M added.
Based on aggregated 13F filings for Q4 2016.